SAPHNELO self-administration TULIP-SC Phase III trial meets primary endpoint in patients with systemic lupus erythematosus based on an interim analysis

Core Insights - Positive high-level results from the interim analysis of the Phase III TULIP-SC trial indicate that AstraZeneca's SAPHNELO® (anifrolumab) significantly reduces disease activity in patients with systemic lupus erythematosus (SLE) compared to placebo [1] - The safety profile observed in the interim analysis aligns with the known clinical profile of SAPHNELO® [1]